Trial · NCT01485172
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline (BL) in Unified Parkinson Disease (PD) Rating Scale (UPDRS) Motor Score | Baseline and Week 4 of the Maintenance Period (Study Week 17) | Intent to Treat (ITT) Population: all randomized subjects who received at least one dose of study medication, had a Baseline efficacy assessment for the specific outcome, and had at least one respective efficacy outcome assessment collected after randomization (Baseline) visit, i.e. had at least one respective Post-Baseline efficacy assessment. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Number of Participants With a >=5 Points Reduction From Baseline in UPDRS Motor Score | Baseline and Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Participants | NUMBER |
| SECONDARY | Number of Participants With a >=10 Points Reduction From Baseline in UPDRS Motor Score | Baseline and Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Participants | NUMBER |
| SECONDARY | Number of Participants With a >=10 Points Reduction From Baseline in UPDRS Parts II and III Combined | Baseline and Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Participants | NUMBER |
| SECONDARY | Responder Rate Defined as Participants With a >=30% Reduction in Baseline UPDRS Motor Score | Baseline and Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Percentage of Participants | NUMBER |
| SECONDARY | Change From Baseline in UPDRS Parts II and III Combined | Baseline and Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Scores on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in UPDRS Activities of Daily Living | Baseline and Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Total UPDRS Score (Parts I-III) | Baseline and Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the UPDRS Part I (Mentation) | Baseline and Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Responder Rate According to the Clinical Global Impression - Global Improvement (CGI-I) Scale | Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Withdrawn From the Study Due to Lack of Efficacy | Up to Week 4 of the Maintenance Period (Study Week 17) | ITT Population. All participants with a non-missing efficacy observation at Baseline and during the maintenance period were analyzed | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01485172/outcomes